<DOC>
	<DOC>NCT01351610</DOC>
	<brief_summary>MSC_Apceth are GMP-manufactured, autologous ex-vivo expanded non-hemapoietic bone-marrow derived stem cells for the treatment of Critical Limb Ischemia</brief_summary>
	<brief_title>Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia</brief_title>
	<detailed_description />
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<criteria>1. Patients with peripheral arterial occlusive disease (symptomatic PAOD), diagnosis of CLI defined as persistent, recurring ischemic rest pain for at least 2 weeks, and/or ulceration or gangrene of the foot or toe, with an ABPI &lt;/= 0.5, 2. Patients with staging of ≥III according to Fontaine and ≥4 according to Rutherford categories, 3. Patients fulfilling the criteria for an invasive revascularisation procedure (PTA) at the discretion of the investigator, 4. Patients without major amputation of the lower extremities within the period of 6 months after inclusion in the opinion of the investigator, 1. Patients with wounds of a severity of greater than grade 2 on the Wagner Scale, 2. Patients with lifethreatening ventricular arrhythmia, 3. Patients with unstable angina pectoris, 4. Patients with severe congestive heart failure (i.e. NYHA Stage IV), 5. Patients with uncontrolled hypertension (defined as diastolic blood pressure &gt;110 mmHg or systolic blood pressure &gt;180 mmHg during screening), 6. Patients with an uncontrolled diabetes mellitus (HbA1c &gt; 9%), 7. Patients having any history of malignant tumour in the anamnesis or are currently on tumour treatment, 8. Patients who are unsuitable for a MSC stem cell therapy in the opinion of the investigator,</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Critical Limb Ischemia</keyword>
	<keyword>Peripheral Arterial Occlusive Disease</keyword>
	<keyword>Peripheral Artery Disease</keyword>
	<keyword>Peripheral Vascular Disease</keyword>
	<keyword>Stem Cell Therapy</keyword>
	<keyword>Mesenchymal Stem Cells</keyword>
</DOC>